NCT07625917Recruiting
Feasibility of Internet-based HIV Prevention Research
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
The study will use social media to recruit a diverse sample of people who self-report injecting drugs, assessing the feasibility of online assessments and participants' ability to perform at-home self-administered HIV testing. Participants will complete online questionnaires at baseline and will be mailed HIV testing kits that they will self-administer and mail to a central laboratory. Investigators will track completion of questionnaires and whether at-home self-administered HIV tests were completed and sent to the laboratory.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 29 May 2026
- Start date
- 1 Aug 2025
- Primary completion date
- 29 May 2028
- Lead sponsor
- Montefiore Medical Center
- Diseases
- HIV
- NCT number
- NCT07625917
What you commit to
- Study type: Interventional
- Planned participants: 500
- From 1 Aug 2025 to the primary completion date, 29 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HIV status known to be positive
Who the study is looking for
- 18 years or older
- US residency
- English or Spanish fluency
- injection drug use (self-report, past 30 days)
- basic reading comprehension
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Montefiore Medical Center Coordinator of this site? Confirm its status | The Bronx | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.